Fact CheckerSign in

NCT04899895Enrolling by invitation

Rheumatology Biorepository

Source: ClinicalTrials.gov · Last updated 9 Feb 2026

Brief summary (registry, in English)

The Biorepository is a prospective observational cohort study for patients under the care of a licensed physician or qualified physician extender. Target minimum enrollment is approximately 3,000 patients within the first 5 years of the study with no defined upper limit of enrollment. Sites from Corrona's current North America network will be asked to participate. Participating sites and subjects will not receive results from any laboratory testing conducted on the Samples. Personal identifying information will not be collected along with the Samples. Subjects will provide informed consent to contribute Samples to include blood (serum, plasma, whole blood) to the Biorepository. In the future, Subjects may be asked to contribute other samples (i.e. saliva, urine, stool) and an additional informed consent will be obtained. Subjects will retain the right to withdraw their consent for use of their Samples at any time. In such case, Corrona will destroy any unused/remaining Samples in its possession.

Status (registry)
Enrolling by invitation
Study type
Observational
Enrollment
3000 (estimated)
First submitted
3 May 2021
Start date
10 Mar 2021
Primary completion date
31 Dec 2100
Lead sponsor
CorEvitas
NCT number
NCT04899895

What you commit to

  • Study type: Observational
  • Planned participants: 3000
  • From 10 Mar 2021 to the primary completion date, 31 Dec 2100
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Criteria the registry did not label

  • A patient must satisfy all of the following criteria to be eligible for enrollment in the Biorepository study .1)Patient is currently participating in a Registry or is eligible to participate and enrolls in a Registry prior to enrollment in the Biorepository study.
  • 2)Patient is starting an Eligible Medication\*with no prior exposure to the specific medication being prescribed.
  • 3)Patient is able to complete Sample collection within fourteen (14) days prior to receiving thefirst dose of the Eligible Medication.

Age in the registry: 18 years to - · Sex: All

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Corrona, LLC
Coordinator of this site? Confirm its status
WalthamUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.